Clinical Trial Update: A Phase Ib Study of HS-10504 Combined Therapy in NSCLC [Phase 1]

View source ↗

Summary

A Phase Ib trial of HS-10504 in combination therapy for non-small cell lung cancer is registered and not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HS-10504

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Lung Cancer | Phase 1 | Status: NOT_YET_RECRUITING